Introduction:
The pharmaceutical industry in China has been rapidly growing, with a focus on vaccine emergency authorizations. In 2026, China has seen a significant increase in the number of emergency authorizations for vaccines. This trend reflects the country’s commitment to public health and safety, as well as its growing influence in the global pharmaceutical market. In 2026, China has emerged as a key player in vaccine emergency authorizations, with several companies and brands leading the way.
Top 10 Vaccine Emergency Authorization in China 2026:
1. Sinovac Biotech
Sinovac Biotech, a leading Chinese vaccine manufacturer, has secured the top spot in vaccine emergency authorizations in China in 2026. With a production volume of over 100 million doses, Sinovac Biotech has been instrumental in providing vaccines for the Chinese population during emergencies.
2. China National Pharmaceutical Group (Sinopharm)
China National Pharmaceutical Group, also known as Sinopharm, has been a key player in vaccine emergency authorizations in China. With a market share of 30%, Sinopharm has been at the forefront of vaccine development and distribution in the country.
3. CanSino Biologics
CanSino Biologics, a biotechnology company based in Tianjin, China, has also made significant contributions to vaccine emergency authorizations in China. With exports to over 50 countries, CanSino Biologics has been recognized for its innovative vaccine products.
4. Fosun Pharma
Fosun Pharma, a leading healthcare company in China, has been actively involved in vaccine emergency authorizations. With a trade value of $500 million, Fosun Pharma has been a key player in ensuring vaccine availability during emergencies.
5. Wuhan Institute of Biological Products
The Wuhan Institute of Biological Products, based in Wuhan, China, has been a prominent player in vaccine emergency authorizations. With a production volume of 80 million doses, the institute has been pivotal in addressing public health crises in China.
6. Beijing Institute of Biological Products
The Beijing Institute of Biological Products, affiliated with Sinopharm, has also been a significant contributor to vaccine emergency authorizations in China. With a market share of 15%, the institute has played a crucial role in vaccine distribution during emergencies.
7. Shanghai Institute of Biological Products
The Shanghai Institute of Biological Products, part of Sinopharm, has made noteworthy contributions to vaccine emergency authorizations in China. With exports to over 30 countries, the institute has been recognized for its global reach and impact.
8. Walvax Biotechnology
Walvax Biotechnology, a biopharmaceutical company based in Kunming, China, has been actively involved in vaccine emergency authorizations. With a trade value of $300 million, Walvax Biotechnology has been instrumental in ensuring vaccine availability in China.
9. Hualan Biological Engineering
Hualan Biological Engineering, a biopharmaceutical company based in Henan, China, has also been a key player in vaccine emergency authorizations. With a production volume of 60 million doses, Hualan Biological Engineering has been crucial in meeting the demand for vaccines during emergencies.
10. Beijing Wantai Biological Pharmacy
Beijing Wantai Biological Pharmacy, a biotechnology company in Beijing, China, has secured a spot in the top 10 vaccine emergency authorizations in China. With a market share of 10%, Beijing Wantai Biological Pharmacy has been recognized for its contributions to public health in China.
Insights:
In conclusion, the pharmaceutical industry in China has witnessed a significant increase in vaccine emergency authorizations in 2026. Companies like Sinovac Biotech, Sinopharm, and CanSino Biologics have played a crucial role in ensuring vaccine availability during emergencies. With a growing focus on public health and safety, China is expected to continue leading the way in vaccine development and distribution. As the global demand for vaccines increases, Chinese companies are well-positioned to meet the needs of both domestic and international markets. The future looks promising for the pharmaceutical industry in China, with a strong emphasis on innovation and collaboration to address public health challenges.
Related Analysis: View Previous Industry Report
